Quintiles Unveils Solution Design Studio
A healthcare technology and apps accelerator, combining expert teams and agile processes in a highly collaborative, digitally enabled environment
RESEARCH TRIANGLE PARK, N.C. - Quintiles, the world’s largest provider of product development and integrated healthcare services, opened its global Solution Design Studio where expert teams will collaborate to create technology solutions that tackle some of healthcare’s biggest challenges. The Studio is a highly interactive technology-driven environment featuring digital-simulation capabilities and proven early-development processes that drive innovation and rapid problem solving. Quintiles’ customers, its therapeutic and domain experts and key healthcare stakeholders will join the Studio’s team of simulation analysts, wearable and virtual reality experts, user-interface designers and app developers. Working together, they can create technology solutions that exceed expectations and delight users, from researchers through healthcare workers and ultimately patients. “We believe that the future of healthcare is intertwined with technology innovation and its application in real-world settings," said Richard Thomas, Quintiles president, Technology & Solutions. “Simply put, we are working with stakeholders to rapidly create technology solutions that solve healthcare challenges, big and small." The new Studio is part of the Quintiles campus, located in the technology hub of Research Triangle Park in North Carolina. The Solution Design Studio team has an award-winning portfolio of digital innovations including the Quintiles Infosario One mobile app, the next-generation clinical development platform, Infosario Design, and Quintiles’ contribution to the Apple ResearchKit framework. Learn more about Quintiles’ Solution Design Studio
here
.
About Quintiles
Quintiles helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit
www.quintiles.com
.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
